Abstract |
Mevinolin, a competitive inhibitor of the rate-limiting enzyme in cholesterol biosynthesis, is an effective hypocholesterolemic agent in patients with primary hypercholesterolemia when given in a twice-daily regimen. The present study compares the hypocholesterolemic effects of mevinolin given in a twice-daily dosage regimen with the same total dosage given either once in the morning or once in the evening in 12 patients with heterozygous familial hypercholesterolemia. Ten patients took a total daily dose of 40 mg of mevinolin and two took 20 mg. On the twice-daily dosage regimen, plasma concentrations of total cholesterol decreased 29.5% and 35.9% as compared with 21.4% and 26.9% with mevinolin given once in the morning and 27% and 32.2% with the drug given once in the evening. These values are all significantly different from baseline, but differences between the three treatment regimens do not reach statistical significance (P = 0.07 for the twice-daily versus once-in-the-morning dosage regimens). We conclude that once-daily administration of mevinolin, particularly in the evening, is an effective hypocholesterolemic regimen in patients with familial hypercholesterolemia.
|
Authors | D R Illingworth |
Journal | Clinical pharmacology and therapeutics
(Clin Pharmacol Ther)
Vol. 40
Issue 3
Pg. 338-43
(Sep 1986)
ISSN: 0009-9236 [Print] United States |
PMID | 3638181
(Publication Type: Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Cholesterol, HDL
- Cholesterol, LDL
- Naphthalenes
- Triglycerides
- Cholesterol
- Lovastatin
|
Topics |
- Adult
- Aged
- Cholesterol
(blood)
- Cholesterol, HDL
(blood)
- Cholesterol, LDL
(blood)
- Drug Administration Schedule
- Female
- Heterozygote
- Humans
- Hyperlipoproteinemia Type II
(drug therapy, genetics)
- Lovastatin
- Male
- Middle Aged
- Naphthalenes
(administration & dosage)
- Triglycerides
(blood)
|